Screener
ICU Medical ICUI R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by ICU Medical in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ICU Medical’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000883984-26-000041
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| GROSS PROFIT | 235,053 | 208,064 | 441,279 | 418,173 |
| OPERATING EXPENSES: | ||||
| Selling, general and administrative | 151,922 | 159,392 | 306,488 | 316,625 |
| Research and development | 22,702 | 21,867 | 43,982 | 45,158 |
| Restructuring, strategic transaction and integration | 21,302 | 16,218 | 38,103 | 32,915 |
| TOTAL OPERATING EXPENSES | 195,926 | 197,477 | 388,573 | 394,698 |
| INCOME FROM OPERATIONS | 39,127 | 10,587 | 52,706 | 23,475 |
| INTEREST EXPENSE, NET | (15,747) | (20,549) | (32,241) | (42,580) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is ICU Medical's R&D?
- ICU Medical (ICUI) reported R&D of $22.7M in Q2 2026.
- How has ICU Medical's R&D changed year-over-year?
- ICU Medical's R&D increased by 3.8% year-over-year, from $21.87M to $22.7M.
- What is the long-term trend for ICU Medical's R&D?
- Over 4 years (2021 to 2025), ICU Medical's R&D has grown at a 16.5% compound annual growth rate (CAGR), from $47.5M to $87.5M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about ICU Medical's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude